Drugs / BI 474121
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05451095 | Nov 2022 → Jun 2023 | — | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT04964453 | Jul → Nov 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04716894 | Feb → Apr 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04672954 | Jan → Jul 2021 | — | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT04537897 | Oct 2020 → Oct 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04194645 | Jan 2020 → Mar 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 474121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04716894 ↗ |
| Route | Oral | “following oral administration of single rising doses.” NCT04194645 ↗ |